PremiumThe FlyMirum Pharmaceuticals price target raised to $76 from $74 at Citizens JMP Mirum Pharmaceuticals Reports Robust Q1 2025 Growth Mirum Pharmaceuticals: Strong Financial Performance and Promising Prospects Justify Buy Rating PremiumThe FlyMirum Pharmaceuticals partner Takeda receives approval for Livmarli in Japan Mirum Pharmaceuticals: Promising Growth Trajectory with Strategic Focus and Pipeline Progress Mirum Pharmaceuticals: Strong Buy Rating Driven by Promising Financial Growth and Clinical Advancements PremiumRatingsPromising Growth and Strategic Positioning Make Mirum Pharmaceuticals a Compelling Buy Mirum Pharmaceuticals: Strong Financial Performance and Strategic Advancements Drive Buy Rating Mirum Pharmaceuticals Reports Strong 2024 Growth 
